{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:46:54Z","timestamp":1782928014144,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijcard.2026.134632","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T06:14:59Z","timestamp":1782108899000},"page":"134632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Editorial on \u201cGLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated lip(a) levels: A multicenter retrospective study\u201d IJCJOURNAL-D-26-01993R1"],"prefix":"10.1016","volume":"460","author":[{"given":"Graham B.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2026.134632_bb0005","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2026.134588","article-title":"GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: a multicenter retrospective study","volume":"459","author":"Mahmoud","year":"2026","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134632_bb0010","doi-asserted-by":"crossref","first-page":"1545787","DOI":"10.3389\/fcvm.2025.1545787","article-title":"Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to lipoprotein (a) testing","volume":"12","author":"Wedemeyer","year":"2025","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcard.2026.134632_bb0015","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijcard.2026.134632_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004871","article-title":"Glucagon-like peptide-1 receptor agonists for obesity: growing popularity met with growing questions over safety","volume":"23","author":"Chao","year":"2026","journal-title":"PLoS Med."},{"key":"10.1016\/j.ijcard.2026.134632_bb0025","article-title":"Capitalizing on the GLP-1 RA revolution for behavioral health through digital companions","volume":"11","author":"Naegele","year":"2025","journal-title":"Digit Health"},{"key":"10.1016\/j.ijcard.2026.134632_bb0030","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug\u2212drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijcard.2026.134632_bb0035","series-title":"Applied Artificial Intelligence for Drug Discovery","article-title":"Federated learning in drug discovery: challenges, innovations, and future directions","author":"Savoia","year":"2026"},{"key":"10.1016\/j.ijcard.2026.134632_bb0040","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","article-title":"How much does it cost to research and develop a new drug? A systematic review and assessment","volume":"39","author":"Schlander","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1016\/j.ijcard.2026.134632_bb0045","doi-asserted-by":"crossref","first-page":"102214","DOI":"10.1016\/j.xcrm.2025.102214","article-title":"The expanding benefits of GLP-1 medicines","volume":"6","author":"Gonzalez-Rellan","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2026.134632_bb0050","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41467-025-67701-9","article-title":"Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases","volume":"17","author":"Kong","year":"2026","journal-title":"Nat. Commun."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326004821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326004821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:01:30Z","timestamp":1782925290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527326004821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"alternative-id":["S0167527326004821"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134632","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Editorial on \u201cGLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated lip(a) levels: A multicenter retrospective study\u201d IJCJOURNAL-D-26-01993R1","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134632","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134588","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"134632"}}